Fuso, PaolaDi Salvatore, MariantoniettaSantonocito, ConcettaGuarino, DonatellaAutilio, ChiaraMulè, AntoninoArciuolo, DamianoRinninella, AntoninaMignone, FlavioRamundo, MatteoDi Stefano, BrunellaOrlandi, ArmandoCapoluongo, EttoreNicolotti, NicolaFranceschini, GianlucaMartín Sánchez, AlejandroTortora, GiampaoloScambia, GiovanniBarone, CarloCassano, Alessandra2023-06-162023-06-162021-08-202075-442610.3390/jpm11080816https://hdl.handle.net/20.500.14352/4934Background: The aim of this study is to identify miRNAs able to predict the outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). Patients and methods: We retrospectively analyzed 24 patients receiving NAC and not reaching pathologic complete response (pCR). miRNAs were analyzed using an Illumina Next-Generation-Sequencing (NGS) system. Results: Event-free survival (EFS) and overall survival (OS) were significantly higher in patients with up-regulation of let-7a-5p (EFS p = 0.006; OS p = 0.0001), mirR-100-5p (EFS s p = 0.01; OS p = 0.03), miR-101-3p (EFS p = 0.05; OS p = 0.01), and miR-199a-3p (EFS p = 0.02; OS p = 0.01) in post-NAC samples, independently from breast cancer subtypes. At multivariate analysis, only let-7a-5p was significantly associated with EFS (p = 0.009) and OS (p = 0.0008). Conclusion: Up-regulation of the above miRNAs could represent biomarkers in breast cancer.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/jpm11080816https://www.mdpi.com/2075-4426/11/8/816/htmopen accesssubtypes breast cancermiRNAsbreast cancer treatmentchemotherapyintegrated therapiesnext-generation-sequencingtarget therapyprecision medicinepersonalized medicineOncología3201.01 Oncología